Pat Cook

3.3k total citations · 1 hit paper
23 papers, 2.3k citations indexed

About

Pat Cook is a scholar working on Surgery, Molecular Biology and Neurology. According to data from OpenAlex, Pat Cook has authored 23 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 7 papers in Molecular Biology and 6 papers in Neurology. Recurrent topics in Pat Cook's work include Testicular diseases and treatments (18 papers), Neuroblastoma Research and Treatments (6 papers) and Ovarian cancer diagnosis and treatment (6 papers). Pat Cook is often cited by papers focused on Testicular diseases and treatments (18 papers), Neuroblastoma Research and Treatments (6 papers) and Ovarian cancer diagnosis and treatment (6 papers). Pat Cook collaborates with scholars based in United Kingdom, United States and Norway. Pat Cook's co-authors include Sally Stenning, Peter Fayers, A. Cuschieri, J W L Fielding, V Joypaul, J Bancewicz, John Craven, Graham M. Mead, A. Horwich and M C Parkinson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Urology.

In The Last Decade

Pat Cook

23 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial

1996 805 citations A. Cuschieri, V Joypaul et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pat Cook United Kingdom	14	1.7k	1.1k	471	424	408	23	2.3k
A. Gerl Germany	32	2.2k 1.3×	745 0.7×	544 1.2×	457 1.1×	28 0.1×	74	2.7k
SP Stenning United Kingdom	16	462 0.3×	521 0.5×	110 0.2×	173 0.4×	56 0.1×	41	1.3k
R. Somers Netherlands	23	385 0.2×	1.7k 1.5×	34 0.1×	221 0.5×	155 0.4×	39	2.7k
Federica Bertolini Italy	28	931 0.5×	946 0.8×	53 0.1×	274 0.6×	297 0.7×	120	2.2k
Cécile Guillemet France	17	203 0.1×	964 0.8×	50 0.1×	130 0.3×	280 0.7×	64	1.4k
Theresa S. Emory United States	14	1.2k 0.7×	1.3k 1.1×	40 0.1×	73 0.2×	1.2k 2.9×	20	2.2k
Patrizia Dall’Igna Italy	23	849 0.5×	578 0.5×	121 0.3×	223 0.5×	12 0.0×	96	1.7k
Olivier Collard France	16	182 0.1×	1.1k 0.9×	43 0.1×	145 0.3×	116 0.3×	67	1.6k
Jessica L. Davis United States	18	275 0.2×	1.2k 1.1×	22 0.0×	318 0.8×	106 0.3×	64	1.7k
Luigi Piva Italy	29	1.8k 1.1×	928 0.8×	294 0.6×	651 1.5×	4 0.0×	130	2.6k

Countries citing papers authored by Pat Cook

Since Specialization

Citations

This map shows the geographic impact of Pat Cook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pat Cook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pat Cook more than expected).

Fields of papers citing papers by Pat Cook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pat Cook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pat Cook. The network helps show where Pat Cook may publish in the future.

Co-authorship network of co-authors of Pat Cook

This figure shows the co-authorship network connecting the top 25 collaborators of Pat Cook. A scholar is included among the top collaborators of Pat Cook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pat Cook. Pat Cook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dearnaley, David P., Sophie D. Fosså, S.B. Kaye, et al.. (2005). Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). British Journal of Cancer. 92(12). 2107–2113. 61 indexed citations

Mead, Graham M., M.H. Cullen, Robert Huddart, et al.. (2005). A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. British Journal of Cancer. 93(2). 178–184. 84 indexed citations

Cook, Pat, et al.. (2004). A New Method of Measuring Safety Performance Will Soon Affect the Whole Industry. Proceedings of SPE International Conference on Health, Safety, and Environment in Oil and Gas Exploration and Production. 2 indexed citations

Fosså, Sophie D., Ronald de Wit, J.T. Roberts, et al.. (2003). Quality of Life in Good Prognosis Patients With Metastatic Germ Cell Cancer: A Prospective Study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). Journal of Clinical Oncology. 21(6). 1107–1118. 90 indexed citations

Marshall, Robert J., et al.. (2002). Symptomatic Renal Metastasis of a Testicular Seminoma Mimicking Pelvicaliceal Transitional Cell Carcinoma. The Journal of Urology. 168(2). 634–635. 3 indexed citations

Wit, Ronald de, J.T. Roberts, P M Wilkinson, et al.. (2001). Equivalence of Three or Four Cycles of Bleomycin, Etoposide, and Cisplatin Chemotherapy and of a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. Journal of Clinical Oncology. 19(6). 1629–1640. 219 indexed citations

Fosså, Sophie D., Sally Stenning, A. Gerl, et al.. (1999). Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. British Journal of Cancer. 80(9). 1392–1399. 89 indexed citations

Stenning, Sally, M C Parkinson, Cyril Fisher, et al.. (1999). Postchemotherapy Residual Masses in Germ Cell Tumor Patients. Content, Clinical Features, and Prognosis. The Journal of Urology. 161(6). 2024–2025. 4 indexed citations

Horwich, A., Dirk Th. Sleijfer, S. D. Fosså, et al.. (1998). Randomized Trial of Bleomycin, Etoposide, and Cisplatin Compared With Bleomycin, Etoposide, and Carboplatin in Good-Prognosis Metastatic Nonseminomatous Germ Cell Cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. The Journal of Urology. 159(3). 1099–1100. 11 indexed citations

10.

Harland, S. J., Pat Cook, S.D. Fosså, et al.. (1998). Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group.. PubMed. 160(4). 1353–7. 90 indexed citations

11.

Horwich, A., D.Th. Sleijfer, Sophie D. Fosså, et al.. (1997). Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.. Journal of Clinical Oncology. 15(5). 1844–1852. 220 indexed citations

12.

Duchesne, Gillian, Sally Stenning, Nina Aass, et al.. (1997). Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role. European Journal of Cancer. 33(6). 829–835. 47 indexed citations

13.

Fosså, Sophie D., R.T.D. Oliver, Sally Stenning, et al.. (1997). Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. European Journal of Cancer. 33(9). 1380–1387. 34 indexed citations

14.

Cuschieri, A., V Joypaul, Peter Fayers, et al.. (1996). Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer – results of the MRC randomised controlled trial. The Lancet. 347(9007). 995–999. 4 indexed citations

15.

Cuschieri, A., V Joypaul, Peter Fayers, et al.. (1996). Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Lancet. 347(9007). 995–999. 805 indexed citations breakdown →

16.

Fayers, Peter, Pat Cook, David Machin, et al.. (1994). On the development of the medical research council trial of α‐interferon in metastatic renal carcinoma. Statistics in Medicine. 13(21). 2249–2260. 13 indexed citations

17.

Razis, Evangelia, George Samonis, Pat Cook, et al.. (1994). TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer.. PubMed. 25(3-4). 241–50. 8 indexed citations

18.

Harland, S. J., Pat Cook, S. D. Fosså, et al.. (1993). Risk Factors for Carcinoma in situof the Contralateral Testis inPatients with Testicular Cancer. European Urology. 23(1). 115–119. 21 indexed citations

19.

Mead, Graham M., Sally Stenning, M C Parkinson, et al.. (1992). The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.. Journal of Clinical Oncology. 10(1). 85–94. 131 indexed citations

20.

Read, G., Sally Stenning, M.H. Cullen, et al.. (1992). Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.. Journal of Clinical Oncology. 10(11). 1762–1768. 294 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact